Ohio State-developed drug receives FDA approval for treatment of CLL and SML

(Ohio State University Wexner Medical Center) On Nov. 21, 2019, the US Food and Drug Administration (FDA) approved the use of the drug acalabrutinib for first-line therapy in chronic lymphocytic leukemia and small cell lymphoma. This is the first full approval of the targeted drug therapy, which was developed and tested at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, in collaboration with the pharmaceutical par...